Neurocrine presents new data analyses from KINECT-HD study

Neurocrine (NBIX) Biosciences announced new patient-reported post-hoc data from the KINECT-HD study highlighting significant reductions in both cognitive and motor-related burdens among adults treated for Huntington’s disease chorea with once-daily INGREZZA capsules. KINECT-HD is the first and only clinical study to demonstrate measurable changes in cognitive and motor disease burden with a vesicular monoamine transporter 2 inhibitor in patients treated for chorea. These analyses will be presented at the 2025 Advanced Therapeutics in Movement & Related Disorders Congress hosted by the Parkinson & Movement Disorder Alliance in Washington, D.C. “The KINECT-HD study demonstrated INGREZZA’s ability to significantly reduce chorea, one of the most visible and disruptive symptoms of Huntington’s disease, which often occurs alongside cognitive decline and leads to serious motor challenges,” said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. “These new patient-reported analyses highlight INGREZZA’s ability to reduce additional cognitive and motor-related challenges faced by those living with Huntington’s disease, including memory loss, limitations with mobility and trouble swallowing.” In the 12-week Phase 3 KINECT-HD clinical trial, INGREZZA demonstrated a significant reduction in chorea severity, as measured by the Unified Huntington’s Disease Rating Scale Total Maximal Chorea score. These post-hoc analyses were conducted to assess the effect of INGREZZA on motor and cognitive burden among people with Huntington’s disease chorea using the Huntington’s Disease Health Index, a disease-specific tool that was developed with patients and caregivers to assess disease burden across functional and psychological domains. Mean changes from baseline were evaluated at maintenance across individual items from five HD-HI domains: cognition, mobility/ambulation, abnormal movements, hand/arm function and gastrointestinal health. Outcomes were assessed among “affected” participants, defined as those with a baseline score of at least 2 on a given item. Reductions in scores indicate improvement. At maintenance, INGREZZA demonstrated numerically larger reductions compared with placebo across all 18 cognition items and 32 of the 33 motor items. Statistically significant improvements with INGREZZA were observed across a range of items.